Sigma Planning Corp boosted its stake in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 31.6% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 29,846 shares of the biotechnology company’s stock after acquiring an additional 7,175 shares during the quarter. Sigma Planning Corp owned 0.07% of REGENXBIO worth $564,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. grew its stake in REGENXBIO by 3.8% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 170,714 shares of the biotechnology company’s stock valued at $3,228,000 after acquiring an additional 6,229 shares during the period. Royce & Associates LP boosted its stake in REGENXBIO by 123.6% during the 1st quarter. Royce & Associates LP now owns 182,450 shares of the biotechnology company’s stock worth $3,450,000 after purchasing an additional 100,871 shares during the last quarter. Robeco Institutional Asset Management B.V. acquired a new stake in REGENXBIO during the 1st quarter worth $48,000. Texas Permanent School Fund Corp boosted its stake in REGENXBIO by 10.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 30,395 shares of the biotechnology company’s stock worth $575,000 after purchasing an additional 2,850 shares during the last quarter. Finally, Inspire Investing LLC acquired a new stake in REGENXBIO during the 1st quarter worth $275,000. Institutional investors and hedge funds own 89.57% of the company’s stock.
Analysts Set New Price Targets
Several equities research analysts have issued reports on RGNX shares. Robert W. Baird started coverage on shares of REGENXBIO in a research note on Thursday, June 1st. They set an “outperform” rating and a $42.00 target price on the stock. StockNews.com started coverage on shares of REGENXBIO in a research note on Thursday, May 18th. They set a “hold” rating on the stock. Finally, Chardan Capital reaffirmed a “buy” rating and set a $55.00 target price on shares of REGENXBIO in a research note on Thursday, August 3rd. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $35.67.
REGENXBIO Trading Down 0.4 %
NASDAQ RGNX opened at $17.90 on Friday. REGENXBIO Inc. has a 52 week low of $17.02 and a 52 week high of $34.05. The business’s fifty day simple moving average is $19.08 and its 200-day simple moving average is $20.01.
REGENXBIO (NASDAQ:RGNX – Get Free Report) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.26) by ($0.40). The company had revenue of $19.98 million during the quarter, compared to analysts’ expectations of $34.50 million. REGENXBIO had a negative net margin of 282.72% and a negative return on equity of 56.21%. The firm’s quarterly revenue was down 38.8% on a year-over-year basis. During the same quarter last year, the firm posted ($1.58) earnings per share. As a group, sell-side analysts forecast that REGENXBIO Inc. will post -4.93 EPS for the current fiscal year.
REGENXBIO Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Further Reading
- Five stocks we like better than REGENXBIO
- How to Invest in Lithium and Lithium Stocks
- Investing in Coffee: 3 Great Strategies to Consider
- What Are Utility Stocks? An Overview of the Utilities Sector
- 5 Best Stocks to Buy in a Bear Market
- How Can Investors Use the Dogs of the Dow Strategy?
- 3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for REGENXBIO Inc. (NASDAQ:RGNX – Free Report).
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.
